================================================================================
WHO 2022 vs ICC 2022 DIFFERENTIAL DIAGNOSIS ANALYSIS REPORT
================================================================================

ðŸ“Š SUMMARY
----------------------------------------
Total tests run: 181
Equivalent results: 114 (63.0%)
Different results: 67 (37.0%)

Differences by significance:
  High impact: 34
  Medium impact: 33
  Low impact: 0

ðŸŽ¯ DIFFERENCES BY TEST FOCUS AREA
----------------------------------------
  mds_blast_ranges: 18 differences
  blast_thresholds: 12 differences
  age_dependent_differences: 10 differences
  erythroid_handling: 8 differences
  tp53_terminology: 6 differences
  comutation_patterns: 4 differences
  combination_scenarios: 2 differences
  realistic_clinical_scenarios: 2 differences
  complex_cytogenetics: 2 differences
  therapy_evolution: 2 differences
  therapy_qualifiers: 1 differences

âš ï¸  HIGH IMPACT DIFFERENCES
----------------------------------------
1. Test test_000004 (blast_thresholds)
   WHO: AML with NPM1 mutation (WHO 2022)
   ICC: MDS with excess blasts (ICC 2022)
   Input: blasts=9%

2. Test test_000006 (blast_thresholds)
   WHO: MDS with increased blasts 2 (WHO 2022)
   ICC: AML with in-frame bZIP mutated CEBPA (ICC 2022)
   Input: blasts=10%

3. Test test_000007 (blast_thresholds)
   WHO: MDS with increased blasts 2 (WHO 2022)
   ICC: AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)
   Input: blasts=10%

4. Test test_000010 (blast_thresholds)
   WHO: MDS with increased blasts 2 (WHO 2022)
   ICC: AML with in-frame bZIP mutated CEBPA (ICC 2022)
   Input: blasts=15%

5. Test test_000011 (blast_thresholds)
   WHO: MDS with increased blasts 2 (WHO 2022)
   ICC: AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)
   Input: blasts=15%

6. Test test_000014 (blast_thresholds)
   WHO: MDS with increased blasts 2 (WHO 2022)
   ICC: AML with in-frame bZIP mutated CEBPA (ICC 2022)
   Input: blasts=19%

7. Test test_000015 (blast_thresholds)
   WHO: MDS with increased blasts 2 (WHO 2022)
   ICC: AML with t(9;22)(q34.1;q11.2)/BCR::ABL1 (ICC 2022)
   Input: blasts=19%

8. Test test_000017 (blast_thresholds)
   WHO: AML with CEBPA mutation (WHO 2022)
   ICC: AML, NOS (ICC 2022)
   Input: blasts=20%

9. Test test_000021 (blast_thresholds)
   WHO: AML with CEBPA mutation (WHO 2022)
   ICC: AML, NOS (ICC 2022)
   Input: blasts=25%

10. Test test_000027 (therapy_qualifiers)
   WHO: Acute myeloid leukaemia, unknown differentiation (WHO 2022)
   ICC: AML, NOS, therapy related (ICC 2022)
   Input: blasts=25.0%

ðŸ“ˆ PATTERN ANALYSIS
----------------------------------------
Blast threshold differences:
  9% blasts: 1 cases
  10% blasts: 3 cases
  15% blasts: 3 cases
  19% blasts: 3 cases
  20% blasts: 1 cases
  25% blasts: 1 cases

Therapy qualifier differences:
  Immune interventions: 1 cases

Most common category changes:
  MDS_BLASTS -> MDS_AML_HYBRID: 14 cases
  MDS_BLASTS -> AML_MDS_RELATED: 11 cases
  MDS_BLASTS -> AML_GENETIC: 10 cases
  UNCLASSIFIABLE -> AML_NOS: 8 cases
  UNCLASSIFIABLE -> MDS_AML_HYBRID: 5 cases

================================================================================